

Supporting Information

Thrombin binding aptamer G-quadruplex stabilized by pyrene-modified nucleotides

Matic Kovačič¹, Peter Podbevšek^{1,2}, Hisae Tateishi-Karimata³, Shuntaro Takahashi³, Naoki Sugimoto^{3,4,} and Janez Plavec^{1,2,5,*}*

1 Slovenian NMR Center, National Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia

2 EN-FIST Centre of Excellence, Trg OF 13, SI-1000 Ljubljana, Slovenia

3 Frontier Institute for Biomolecular Engineering Research (FIBER), Konan University, 7-1-20 Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan

4 Graduate School of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, 7-1-20 Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan

5 Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000 Ljubljana, Slovenia




Figure S1. Imino and aromatic regions of ^1H NMR spectra of TBA0, TBA3, TBA7, TBA12 and TBA16 in a 50 mM KCl solution at 25 °C.




Figure S2. A,B) Normalized absorbance spectra of TBA, TBA4, TBA9^M and TBA13 samples. C) CD-spectra of 50 μ M TBA, TBA9^M and TBA13. D) Fluorescence emission spectra of monomeric 150 μ M TBA4, TBA9^M and TBA13 G-quadruplexes in 50 mM KCl solution at 25 $^{\circ}$ C. Excitation wavelength of 330 nm was used.




Figure S3. Imino and aromatic regions of ^1H NMR spectra of TBA, TBA4, TBA9 and TBA13 in a 50 mM NaCl solution at 25 °C.




Figure S4. Imino and aromatic regions of ¹H NMR spectra of 100 μM TBA sample in a 50 mM KCl solution at 25 °C with increasing additions of 1-pyrenesulfonic acid sodium salt. Proton signals of pyrene group are marked with red asterisks.




Figure S5. Imino and aromatic regions of ¹H NMR spectra of TBA4/9, TBA4/13 and TBA9/13 in a 50 mM KCl solution at 25 °C.




Figure S6. Imino regions of 1D ^{15}N -edited HSQC NMR spectra of site-specifically labeled TBA9^D in a 100 mM KCl solution at 25 °C.




Figure S7. (A-D) Normalized UV melting curves for TBA, TBA4, TBA9 and TBA13 at 10, 20, 300 and 400 μM oligonucleotide concentrations in a buffer containing 50 mM KCl. (E) First derivative of absorbance at 295 nm vs temperature for TBA9 at different oligonucleotide concentrations.




Figure S8. Imino and methyl regions of ^1H NMR spectra of TBA9 in a 100 mM KCl solution at temperatures ranging from 25 to 55 $^{\circ}\text{C}$.




Figure S9. Denaturing gel electrophoresis of (a) TBA, (b) TBA4, (c) TBA9, and (d) TBA13 after the addition of human serum at 37 $^{\circ}\text{C}$. Samples incubated for 0, 1, and 3 hours were loaded on lanes 1 to 3, respectively. Lane M indicated a DNA size maker.




Figure S10. Binding assay of pyrene-modified TBA to human thrombin immobilized on quartz crystal microbalance (QCM). (A) Schematic illustration of assay for the binding of pyrene-modified TBA to thrombin by using QCM. (B) Frequency changes of QCM by the addition of native TBA (blue), TBA4 (red), TBA9^M (green), and TBA13 (pink). As a control experiment, antisense of the TBA sequence (Anti TBA; yellow) was injected. Black arrows indicate the timings of injection of the DNAs with the indicated amount. (C) Binding isotherms of pyrene-modified TBA to thrombin immobilized on QCM. All the data were corrected from three individual experiments. All the assays were carried out in potassium buffer pH 6.9 at 25 °C. The plots were fitted by Langmuir adsorption model as follows: $-\Delta F = [\text{DNA}] * (-\Delta F_{\text{max}}) / ([\text{DNA}] + K_D)$.

Table S1. Degradation results of TBA oligonucleotides under human serum conditions.

Oligonucleotide	Incubation time (hours)	Extend of degradation (%)
TBA	0	100
	1	41.6
	3	10.0
TBA4	0	100
	1	72.5
	3	39.8
TBA9	0	100
	1	67.5
	3	28.4
TBA13	0	100
	1	70.2
	3	39.2

Table S2. Binding parameters of pyrene-modified TBA analogues to thrombin immobilized on QCM.

Oligonucleotide	K _D (nM)
TBA	85.1 ± 17.7
TBA4	166 ± 29.3
TBA9	93.6 ± 51.0
TBA13	523 ± 91.6
Anti TBA*	No binding

*Non-binding control DNA sequence is complementary to TBA.